We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Vote to separate consumer healthcare paves way for London’s largest stock market listing in a decade
Pharma companies are hoping to catch up with rivals as they report promising trial results for jab
‘Next-generation’ jab delivers strong immune response against variants
Successful trials for RSV vaccine add much-needed lift to the UK drugmaker’s pipeline
US pharma group to sell down stake in Haleon business after July IPO
Spinning off the business will make more bolt-on deals possible
UK drugmaker to pay $2.1bn upfront plus another potential $1.2bn as it boosts its vaccines business
GSK-controlled company in talks with UN-backed body on generic manufacture of highly effective PrEP injection
UK drugmaker points to ‘good momentum’ as sales rise by a third in ‘landmark year’
Several hundred staff set stage for first walkout in drugmaker’s history
Sierra’s bone marrow cancer treatment had positive clinical trial results in January
Plus, speculation surrounds Ted Baker, and Russian connections give Jefferies an ESG headache
Drugmaker recoups cash from Moncef Slaoui for non-compliance with company policies
As split nears completion, investors turn attention to what comes next
UK drugmaker ‘extremely confident’ despite market uncertainty over Ukraine
Drugmakers to apply for protein-based shot to be used as primary and booster jabs
Quarterly profits at UK drugmaker beat expectations and sales of Covid treatment hit £958mn
Plus, mutual insurers LV and Royal London end talks and BP’s best defence against a windfall tax
The first patient has been given an implant to control rheumatoid arthritis by modifying nerve signals to the spleen
Top shareholder urges executives to improve business rather than chase big acquisitions
Top-10 investor Flossbach ‘would strongly oppose’ a deal for consumer business
Departure of Hal Barron comes as pharma group faces pressure to revive drug pipeline
Rating agency says group risks losing A status that it is determined to retain
Consumer goods group has gems it could sell piecemeal
UK pharma company may still prefer to list its consumer health unit but the bar for success is now higher
International Edition
